Vertex Pharmaceuticals: 2025 TIME100 Most Influential CompaniesBoston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company focusing on developing and commercializing therapies for treating cystic fibrosis (CF).

Vertex said in its WARN letter that the jobs will start ending on Aug. 5, and will consolidate the Providence campus.

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. The main bad news with Vertex's Q1 ...

Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped.

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. Vertex reported Q1 revenue of $2.77 billion, up 3% year over year. In addition, Vertex revealed ...

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% after the bell.